作者: Jing H, et al.

期刊: Cancer Cell

发表日期: 2016年3月14日

期刊卷号和页码: 29(3):297-310

主要内容: 这篇研究文章介绍了一种选择性抑制SIRT2的抑制剂，它能够促进c-Myc癌蛋白的降解，并显示出广泛的抗癌活性。研究表明，SIRT2在多种癌症中起着重要作用，通过抑制SIRT2，可以显著降低c-Myc的稳定性，从而抑制癌细胞的增殖。

Introduction / 引言

This research article introduces a selective SIRT2 inhibitor that promotes the degradation of the c-Myc oncoprotein and exhibits broad anticancer activity. The study shows that SIRT2 plays a crucial role in various cancers, and by inhibiting SIRT2, the stability of c-Myc is significantly reduced, thereby inhibiting cancer cell proliferation.

本研究文章介绍了一种选择性抑制SIRT2的抑制剂，它能够促进c-Myc癌蛋白的降解，并显示出广泛的抗癌活性。研究表明，SIRT2在多种癌症中起着重要作用，通过抑制SIRT2，可以显著降低c-Myc的稳定性，从而抑制癌细胞的增殖。

Research Methods / 研究方法

1. Inhibitor Screening and Identification: A selective SIRT2 inhibitor was identified through high-throughput screening and biochemical analysis.

2. Cell Experiments: The anticancer effect of the inhibitor was tested in various cancer cell lines.

3. Animal Models: The anticancer activity of the inhibitor was validated in mouse models.

1. 抑制剂筛选和鉴定：通过高通量筛选和生化分析鉴定出SIRT2选择性抑制剂。

2. 细胞实验：在多种癌细胞系中测试抑制剂的抗癌效果。

3. 动物模型：使用小鼠模型验证抑制剂的体内抗癌活性。

Research Results / 研究结果

The SIRT2 selective inhibitor significantly reduced the levels of the c-Myc protein. The inhibitor exhibited strong anticancer activity both in vitro and in vivo. The inhibitor was effective against various types of cancer, including breast cancer, lung cancer, and colon cancer.

SIRT2选择性抑制剂显著降低了c-Myc蛋白水平。抑制剂在体外和体内均表现出强大的抗癌活性。该抑制剂对多种癌症类型（如乳腺癌、肺癌、结肠癌）均有效。

Conclusion / 结论

The SIRT2 selective inhibitor demonstrates broad anticancer potential by promoting c-Myc degradation, providing a new strategy for cancer treatment.

该研究表明，SIRT2选择性抑制剂通过促进c-Myc降解显示出广泛的抗癌潜力，为癌症治疗提供了一种新的策略。

CAS Numbers of Related Compounds / 相关化合物的CAS号

AGK2: 304896-28-4

AK-7: 1645286-75-4